HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER		Author Keyword(s) Vol Page [Advanced]

This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this link to a friend Similar articles in ADC Online Similar articles in PubMed Add article to my folders Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Clark, P L Articles by Truog, W E Search for Related Content PubMed PubMed Citation Articles by Clark, P L Articles by Truog, W E

Safety and efficacy of nitric oxide in chronic lung disease

¹ Section of Neonatology, Children's Mercy Hospitals and Clinics, 2401 Gillham Road, Kansas City, MO 64108, USA
² Department of Pediatrics, University of Missouri–Kansas City School of Medicine, Kansas, USA

Correspondence to:
Correspondence to:
Dr Truog, Department of Pediatrics, University of Missouri–Kansas School of Medicine, Kansas City, USA;
wtruog{at}cmh.edu

Background: Therapies for neonatal chronic lung disease (CLD) of prematurity have had limited success.

Aims: To determine whether inhaled nitric oxide (INO) administered to very low birthweight infants with developing CLD might improve oxygenation without adverse effects.

Methods: Subjects were 10–30 days of age, birth weight <1250 g, with developing or established CLD, and requiring mechanical ventilation with mean airway pressure 7 cm H₂O and FIO₂ 0.40. We monitored changes in oxygenation and FIO₂ requirement during treatment with INO (initial dose 20 ppm). Tracheal aspirate samples obtained before, during, and after treatment were analysed for interleukin 1ß (IL-1ß), IL-8, 8-epi-prostaglandin F₂ (8-epi-PGF₂), laminin, and endothelin 1 (ET-1) to assess any potential effects of INO on markers of inflammation peroxidation, basement membrane injury, or vasoactivity.

Results: Thirty three patients met entry criteria. Mean gestational age was 25 (SD 2) weeks; birth weight was 736 (190 g); age of study infants was 19 (6) days (range 9–29). Mean FIO₂ decreased from baseline (0.75) to 0.58 at 72 hours. Duration of therapy was seven days. Tracheal aspirate concentrations of IL-1ß, IL-8, 8-epi-PGF₂, ET-1, and laminin were unchanged between baseline and 48 hours of INO, and 48 hours after discontinuation of INO. No new cases of, nor extension of, intraventricular haemorrhage occurred. Four infants died.

Conclusion: INO (20 ppm) improved oxygenation in most infants with early CLD, without inducing changes in markers of inflammatory or oxidative injury.

Keywords: chronic lung disease; inhaled nitric oxide; lung inflammation; endothelin 1

Abbreviations: CLD, chronic lung disease; CMV, conventional mechanical ventilation; ELISA, enzyme linked immunoassay; HFOV, high frequency oscillatory ventilation; INO, inhaled nitric oxide; IVH, intraventricular haemorrhages; PCA, postconceptional age; PVR, pulmonary vascular resistance; sSC-IgA, soluble secretory component of IgA; VLBW, very low birthweight

This article has been cited by other articles:

				W. E. Truog, P. L. Ballard, M. Norberg, S. Golombek, R. C. Savani, J. D. Merrill, L. A. Parton, A. Cnaan, X. Luan, R. A. Ballard, et al. Inflammatory Markers and Mediators in Tracheal Fluid of Premature Infants Treated With Inhaled Nitric Oxide Pediatrics, April 1, 2007; 119(4): 670 - 678. [Abstract] [Full Text] [PDF]

				R. A. Ballard, W. E. Truog, A. Cnaan, R. J. Martin, P. L. Ballard, J. D. Merrill, M. C. Walsh, D. J. Durand, D. E. Mayock, E. C. Eichenwald, et al. Inhaled nitric oxide in preterm infants undergoing mechanical ventilation. N. Engl. J. Med., July 27, 2006; 355(4): 343 - 353. [Abstract] [Full Text] [PDF]

				A. R. Stark Inhaled NO for preterm infants--getting to yes? N. Engl. J. Med., July 27, 2006; 355(4): 404 - 406. [Full Text] [PDF]

				F. Ichinose, J. D. Roberts Jr, and W. M. Zapol Inhaled Nitric Oxide: A Selective Pulmonary Vasodilator: Current Uses and Therapeutic Potential Circulation, June 29, 2004; 109(25): 3106 - 3111. [Full Text] [PDF]

				I. I. Ekekezie, D. W. Thibeault, S. D. Simon, M. Norberg, J. D. Merrill, R. A. Ballard, P. L. Ballard, and W. E. Truog Low Levels of Tissue Inhibitors of Metalloproteinases With a High Matrix Metalloproteinase-9/Tissue Inhibitor of Metalloproteinase-1 Ratio Are Present in Tracheal Aspirate Fluids of Infants Who Develop Chronic Lung Disease Pediatrics, June 1, 2004; 113(6): 1709 - 1714. [Abstract] [Full Text] [PDF]